Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections

Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 da...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2016-10, Vol.60 (10), p.6365-6368
Main Authors: El Samad, Youssef, Lanoix, Jean-Philippe, Bennis, Youssef, Diouf, Momar, Saroufim, Carlo, Brunschweiler, Benoit, Rousseau, Florence, Joseph, Cédric, Hamdad, Farida, Ait Amer Meziane, Mohamed, Routier, Simon, Schmit, Jean-Luc
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - blood
Anti-Bacterial Agents - therapeutic use
Bone Diseases, Infectious - drug therapy
Bone Diseases, Infectious - microbiology
Clinical Therapeutics
Drug Monitoring
Female
Gram-Positive Bacterial Infections
Gram-Positive Bacterial Infections - drug therapy
Gram-Positive Cocci - pathogenicity
Humans
Injections, Subcutaneous
Joint Diseases - drug therapy
Joint Diseases - microbiology
Life Sciences
Male
Middle Aged
Prospective Studies
Teicoplanin
Teicoplanin - administration & dosage
Teicoplanin - blood
Teicoplanin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 days. Thirty patients with Gram-positive cocci BJI were included. Once the target of 25 to 40 mg/liter trough serum concentration was achieved, treatment was switched from an intravenous to an s.c. route. No discontinuation of teicoplanin related to injection site reaction and no severe local adverse event were observed. On multivariate analysis, better tolerability was observed at the beginning of treatment, in patients over 70 years old, and for dosages less than 600 mg. In conclusion, we recommend s.c. administration of teicoplanin when needed.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00351-16